Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

138.66 -4.52 (-3.16%)
Streaming Delayed Price Updated: 11:02 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma ADR

< Previous 1 2 3 4 5 Next >
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Via Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that have proven fruitful, especially for the Harbor Small Cap Growth Fund, where... 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
Via Benzinga
How Is The Market Feeling About Ascendis Pharma?
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
Ascendis Pharma's Earnings: A Preview
Via Benzinga
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth... 
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
Via Benzinga
Recap: Ascendis Pharma Q3 Earnings
Via Benzinga
Preview: Ascendis Pharma's Earnings
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
Earnings Preview For Ascendis Pharma
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
Via Benzinga
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in  
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Earnings Scheduled For September 5, 2023
Companies Reporting Before The Bell • Procaps Gr (NASDAQ:PROC) is likely to report earnings for its second quarter. 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Where Ascendis Pharma Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors. 
Via SBWire
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.